Apple ( NASDAQ: AAPL ) is the world's largest company by market capitalization, so it takes a lot for companies to surpass it in terms of valuation. However, I think that it's possible. The number of companies in a position to pass Apple is relatively few, based solely on Apple's sheer $3.6 ...

NEW YORK, March 03, 2025 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Walgreens Boots Alliance, Inc. WBA? Did you purchase your shares between April 2, 2020 and January 16, 2025, inclusive? Did you lose money in your investment in Walgreens Boots Alliance, ...

NEW YORK, March 03, 2025 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Manhattan Associates, Inc. MANH? Did you purchase your shares between October 22, 2024 and January 28, 2025, inclusive? Did you lose money in your investment in Manhattan Associates, Inc.?

NEW YORK, March 03, 2025 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Semtech Corporation SMTC? Did you purchase your shares between August 27, 2024 and February 7, 2025, inclusive? Did you lose money in your investment in Semtech Corporation?

NEW YORK, March 03, 2025 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors ( the "Class" ) who purchased or acquired the securities of Rocket Lab USA, Inc. ( "Rocket Lab" or the "Company" ) RKLB between ...

BLUE MOON ANNOUNCES ROBUST RESULTS OF THE PRELIMINARY ECONOMIC ASSESSMENT FOR ITS BLUE MOON VMS DEPOSIT INCLUDING AN AFTER-TAX BASE CASE IRR OF 38% AND ...

ZUG, Switzerland, March 03, 2025 ( GLOBE NEWSWIRE ) -- Pharvaris PHVS, a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema ( HAE ) and acquired ...

ZUG, Switzerland, March 03, 2025 ( GLOBE NEWSWIRE ) -- Pharvaris ( Nasdaq: PHVS ) , a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema ( HAE ) ...

ZUG, Switzerland, March 03, 2025 ( GLOBE NEWSWIRE ) -- Pharvaris ( Nasdaq: PHVS ) , a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema ( HAE ) ...

- Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients -- $0 co-pay for all eligible patients and best-in-class patient support services -- Now available exclusively through Optime Care ...